Zeo ScientifiX, Inc. (ZEOX)
| Market Cap | 12.19M |
| Revenue (ttm) | 4.57M |
| Net Income (ttm) | -4.90M |
| Shares Out | 6.45M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,600 |
| Average Volume | 4,022 |
| Open | 1.750 |
| Previous Close | 1.733 |
| Day's Range | 1.750 - 1.890 |
| 52-Week Range | 1.510 - 4.730 |
| Beta | 5.31 |
| RSI | 44.77 |
| Earnings Date | Jun 13, 2025 |
About Zeo ScientifiX
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. The company’s lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. It also provides Patient Pure X, an autologous blood-derived biologic technology, that helps the body’s natural ability to de... [Read more]
Financial Performance
In 2024, Zeo ScientifiX's revenue was $4.62 million, an increase of 1.36% compared to the previous year's $4.56 million. Losses were -$4.71 million, -32.66% less than in 2023.
Financial StatementsNews
ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation
FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development ...
ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer
FORT LAUDERDALE, FL / ACCESS Newswire / February 18, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and developme...
ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community
FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and developme...
ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss
FORT LAUDERDALE, FL / ACCESSWIRE / November 13, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, announced it has part...
ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians
Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights FORT LAUDERDALE, FL / ACCESSWIRE / October 15, 2024 / ZEO ScientifiX, Inc. ("ZEO" or t...
ZEO ScientifiX Partners with National Provider of Healthcare Services
Physicians Group, LLC's Network Of Clinics And Diverse Patient Population Will Provide ZEO With Exclusive Research-Based Opportunities FORT LAUDERDALE, FL / ACCESSWIRE / October 1, 2024 / ZEO Scientif...
ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research
South Florida Biotech Company Seeks To Expand Its Research Program Into Phase 2 Clinical Trials FORT LAUDERDALE, FL / ACCESSWIRE / September 24, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (O...